Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar pchop123 (76.56) Submitted: 7/26/2012 3:30:02 PM : Outperform Start Price: $6.16 EXEL Score: -7.85

With PE of 9 , this biotech has great treatment for thyroid cancer and perhaps other cancers, so I consider it undervalued

Featured Broker Partners


Advertisement